Arthanib 5 mg (Tofacitinib) Tablets


Arthanib 5 mg (Tofacitinib) Tablets


“Arthanib 5 mg,” developed by Aristopharma Ltd. and supplied by Orio Pharma, represents a significant milestone in the treatment of rheumatoid arthritis (RA). Featuring Tofacitinib, a novel Janus kinase (JAK) inhibitor, Arthanib offers a targeted approach to ease the symptoms of this autoimmune disorder, providing relief and improving the quality of life for individuals affected by RA.

Development by Aristopharma Ltd.:

Aristopharma Ltd.’s contribution to rheumatology is embodied in Arthanib 5 mg. The development of Tofacitinib reflects their dedication to innovative solutions in addressing autoimmune conditions, focusing on enhancing patient outcomes through targeted therapy.

Mechanism of Action:

Tofacitinib, the active ingredient in Arthanib 5 mg, works by inhibiting specific Janus kinases involved in the inflammatory process. This action modulates the immune response, effectively reducing inflammation and alleviating symptoms associated with rheumatoid arthritis.

Clinical Applications:

Arthanib 5 mg is primarily used in the management of:

  1. Moderate to Severe Rheumatoid Arthritis: Particularly effective for adults who have an inadequate response to other disease-modifying antirheumatic drugs (DMARDs), Arthanib 5 mg provides a viable alternative in managing RA.

Dosage and Administration:

The dosage of Arthanib 5 mg is determined by healthcare professionals, considering the severity of RA and the patient’s response to treatment. Administered orally, it can be taken with or without food, and the treatment regimen may be combined with other RA medications as needed.

Benefits of Arthanib 5 mg:

  1. Reduced Joint Pain and Swelling: Arthanib 5 mg effectively decreases joint pain and swelling, offering substantial relief to RA patients.
  2. Improved Physical Function: By mitigating the inflammatory processes of RA, Arthanib enhances patients’ ability to perform daily activities, improving their overall physical functionality.
  3. Slowed Progression of Joint Damage: Tofacitinib has been shown to slow the progression of joint damage, helping to maintain joint integrity over time.

Manufacturing Excellence by Aristopharma Ltd.:

Aristopharma Ltd. is recognized for its commitment to producing high-quality pharmaceuticals. The manufacturing of Arthanib 5 mg is a testament to their excellence in pharmaceutical production, adhering to the highest standards of safety and efficacy.

Distribution by Orio Pharma:

Orio Pharma plays a vital role in distributing Arthanib 5 mg, ensuring its availability to healthcare providers and patients. Their expertise in supply chain management guarantees a reliable and efficient delivery of this essential medication.


Arthanib 5 mg (Tofacitinib) signifies an important advancement in the treatment of rheumatoid arthritis. The collaboration between Aristopharma Ltd. and Orio Pharma has brought forth a medication that not only treats RA but also offers a ray of hope for individuals seeking to regain control over their lives.

The targeted mechanism of Tofacitinib in addressing the inflammatory pathways of RA highlights its role as an effective and well-tolerated treatment option. This partnership ensures the highest standards of manufacturing and accessibility, making a significant impact on the lives of those affected by RA.

As the field of rheumatoid arthritis treatment continues to evolve, Arthanib 5 mg exemplifies the progress being made in offering more effective, personalized, and compassionate care. It stands as a testament to the ongoing commitment of Aristopharma Ltd. and Orio Pharma in advancing the field of rheumatology and improving patient outcomes.